Pacira BioSciences’ (PCRX) Overweight Rating Reaffirmed at Piper Sandler

Piper Sandler reaffirmed their overweight rating on shares of Pacira BioSciences (NASDAQ:PCRX) in a research report report published on Wednesday, Benzinga reports. Piper Sandler currently has a $42.00 price objective on the stock.

A number of other equities analysts also recently weighed in on PCRX. Barclays downgraded shares of Pacira BioSciences from an overweight rating to an equal weight rating and lowered their target price for the stock from $38.00 to $25.00 in a research note on Wednesday. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a research report on Thursday, March 7th. They set an overweight rating and a $45.00 target price on the stock. Needham & Company LLC reissued a buy rating and issued a $43.00 price target on shares of Pacira BioSciences in a research note on Tuesday. Finally, HC Wainwright restated a buy rating and set a $57.00 price target on shares of Pacira BioSciences in a report on Tuesday. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and a consensus price target of $46.10.

Pacira BioSciences Trading Down 4.7 %

NASDAQ PCRX opened at $21.66 on Wednesday. Pacira BioSciences has a 12 month low of $20.52 and a 12 month high of $40.16. The company has a current ratio of 5.81, a quick ratio of 4.78 and a debt-to-equity ratio of 0.57. The firm has a market capitalization of $1.01 billion, a PE ratio of 15.15 and a beta of 0.88. The business’s 50-day moving average price is $28.60 and its two-hundred day moving average price is $29.73.

Pacira BioSciences (NASDAQ:PCRX) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). Pacira BioSciences had a return on equity of 12.98% and a net margin of 10.34%. The firm had revenue of $167.12 million for the quarter, compared to the consensus estimate of $165.43 million. On average, analysts expect that Pacira BioSciences will post 2.13 EPS for the current year.

Insider Transactions at Pacira BioSciences

In other Pacira BioSciences news, insider Jonathan Slonin sold 2,836 shares of Pacira BioSciences stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the transaction, the insider now owns 95,557 shares in the company, valued at approximately $2,699,485.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Lauren Riker sold 3,970 shares of the firm’s stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $28.72, for a total transaction of $114,018.40. Following the transaction, the senior vice president now directly owns 38,075 shares of the company’s stock, valued at $1,093,514. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Slonin sold 2,836 shares of the company’s stock in a transaction dated Tuesday, July 2nd. The stock was sold at an average price of $28.25, for a total transaction of $80,117.00. Following the completion of the sale, the insider now directly owns 95,557 shares of the company’s stock, valued at $2,699,485.25. The disclosure for this sale can be found here. Insiders sold a total of 21,150 shares of company stock valued at $602,170 over the last three months. Corporate insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the business. ICA Group Wealth Management LLC bought a new stake in Pacira BioSciences during the fourth quarter worth $30,000. GAMMA Investing LLC increased its position in shares of Pacira BioSciences by 229.6% during the 2nd quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock valued at $38,000 after purchasing an additional 932 shares during the last quarter. Park Place Capital Corp bought a new stake in shares of Pacira BioSciences during the 2nd quarter worth $46,000. Quadrant Capital Group LLC boosted its holdings in shares of Pacira BioSciences by 61.5% in the 4th quarter. Quadrant Capital Group LLC now owns 2,324 shares of the company’s stock worth $78,000 after buying an additional 885 shares during the last quarter. Finally, Cape Investment Advisory Inc. bought a new position in Pacira BioSciences during the fourth quarter valued at about $97,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.